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Summanr The mechanism of down-regulation of c-mvc RNA associated With androgen-induced suppression
of the transformed phenotype in the human prostate carcinoma cell line LNCaP was investigated. The
synthetic androgen mibolerone (7a-17x-Dimethvl-19-nortestosterone) reversibly inhibits the proliferation of
LNCaP cells and. from 12-72 h after hormone addition reduces the level of c-mv c transcripts to a few- per cent
of controls. P,. P. and PO c-mwc transcripts decline at the same rate. whereas P, transcripts are much less
hormone sensitive. Nuclear run-on analysis revealed that c-mvc is dow%n-regulated at the level of transcription
initiation in LNCaP cells. The level of c-mYc transcripts prevailing in untreated control cells can be restored in
androgen-induced cells by excess antiandrogen. indicating the insolvement of the androgen receptor in c-mYc
dow-n-regulation.
The cellular proto-oncogene c-mvc is known to be involved
in the regulation of cell growth and differentiation (for review
see Cole. 1986). The level of c-mwc RNA is invariably higher
in proliferating than in quiescent cells. and remains roughly
constant throughout the cell cycle (Thompson et al.. 1985).
C-mvc RNA is markedly induced upon stimulation of resting
cells by mitogens to pass from Go to G1 (Kelly et al.. 1983:
Campisi et al.. 1984). In complementary experiments. c-mvc
RNA levels fall dramatically when cells withdraw from the
cell cycle into Go or undergo terminal differentiation (for
review see Spencer & Groudine. 1990). Steady state levels of
c-m} c RNA are subject to distinct control mechanisms:
exceptionally short half-life of c-mvc RNA (Dani et al.. 1984:
Piechaczyk et al.. 1987). impaired maturation of the primanr
transcript (Eick. 1990). and a block to RNA-elongation at
the first exon-intron border (Bentley & Groudine. 1986a:
Eick & Bornkamm. 1986) as rapid means of c-mwc regula-
tion. and modulation of the rate of initiation as a late acting
mechanism (Siebenlist et al.. 1988).
The structure of the gene with two major. PI and P2
(Battey et al.. 1983). and two minor. P; and P0 (Bentley &
Groudine. 1986a: ar-Rushdi et al.. 1983; Hayday et al.. 1984;
Bentley & Groudine. 1986b). sites of transcription initiation
has been well characterised. Additionally. positive and
negative regulatory elements have been found within or
flanking the human and mouse c-m} c gene (Yang et al..
1986: Chung et al.. 1986: Remmers et al.. 1986: Lipp et al..
1987: Kakkis & Calame. 1987: Hay et al.. 1987: Iguchi-Ariga
et al.. 1988; Weisinger et al.. 1988: Asselin et al.. 1989: Hall.
1990) which may modulate initiation (Thalmeier et al.. 1989:
Pietenpol et al.. 1990; Hall. 1990; Sacca & Cochran. 1990)
and elongation of transcription (Bentley & Groudine. 1988:
Miller et al.. 1989). Several transcription factors have been
described which bind to sequences upstream of c-myc includ-
ing NFl (Siebenlist et al.. 1984), AP2 (Imagawa et al.. 1987).
APl. and octamer binding factors (Takimoto et al.. 1989:
Hay et al.. 1989). NFkB (Duyao et al.. 1990). and a mouse
plasmacytoma specific repressor protein (Kakkis et al.. 1989).
Stimuli from steroid hormones are generally considered to
have a key-role in regulating cell proliferation and tissue
development. Despite the increasing molecular data on
steroid hormone-receptor complex action on individual res-
ponse elements (for review see Beato. 1989). until no%. the
intricate cell-biological processes leading from hormonal sig-
nals to the modulation of cell proliferation remain poorlv
defined. Cell cycle arrest associated with c-m! c down-
regulation by steroid hormones has hitherto been described
in lymphocytes and promyelocytes. Glucocorticoids block
lymphocytes and lymphoma cells at the G1 phase of the cell
cycle. Among a panel of known growth-related genes. only
c-m} c expression was reduced by dexamethasone (Yuh &
Thompson. 1989). In a T lymphoblastic leukaemic cell line.
immediate post-transcriptional down-regulation of c-mwc has
been demonstrated in response to glucocorticoids (Maroder
et al.. 1990).
In the promyelocytic cell line HL60. 1.215-Dihvdroxv-
vitamin D, (1.25-(OH)Dd>-induced differentation along the
monocyte lineage is preceded by a decrease in the steadv
state level of c-mwc RNA (Reitsma et al.. 1983). The 1.25-
(OH)2D3 effect on c-mvc RNA was shown to occur at the
transcnptional level (Simpson et al.. 1987).
Androgen analogues containing a 17x-methyl-testosterone
backbone inhibit the proliferation (Sonnenschein et al.. 1989)
and suppress the transformed phenotype (Wolf et al.. 1991)
in the androgen responsive (Horoszewicz et al.. 1983: Schulz
et al.. 1985: Berns et al.. 1986) human prostate carcinoma cell
line LNCaP (Horoszewicz et al.. 1980). The androgen recep-
tor of LNCaP cells carries a point mutation in the steroid
binding domain but activates transcription in an androgen-
dependent manner (Veldscholte et al.. 1990). LNCaP cells are
considered to be the best-suited in *itro model of prostate
cancer available (Thompson. 1990). Recently we could show
that the synthetic androgen mibolerone represses anchorage-
independent growth and concomitantly reduces the level of
c-mwc RNA in LNCaP cells (Wolf et al.. 1991). Here we have
studied the details of hormonal c-myc repression. We demon-
strate late transcriptional repression of the Pl. P2 and P0
promoters of c-mYc.
Materials and methods
Cell culture and hormones
The prostate carcinoma cell line LNCaP (HoroszeWicz et al..
1980) was from the Human Tumor Cell Laboratory. Sloan
Kettering Institute for Cancer Research. Rye. NY. LNCaP
cells between passages 75 and 90 were used for the
experiments described. Cells were maintained in RPMI
medium as monolayers in the presence of 10% FCS and
phenol red. For the preparation of seed stocks, cells were
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grown to 50 to 75% confluency before use. Hormones were
added 48 h after seeding as ethanol solutions to give a final
concentration as indicated in the figures. Synthetic androgen:
7a-17x-Dimethyl-19-nortestosterone (mibolerone; Upjohn).
Antiandrogen: 6-chloro-dehydro-17a-acetoxy-lI.2a-methylene-
progesterone (cyproterone acetate. CA, Schering).
RNA extraction and Northern blor analysis
Standard protocols were followed as described elsewhere (Wolf
et al.. 1991).
SI mapping
Single-stranded uniformly labelled DNA probes were prepared
by pnrmer extension of M13 clones, double-stranded probes by
end-labelling with T4-polynucleotide kinase. Hvbridisation of
labelled DNA fragments to total RNA was caried out using a
modification of the method of Berk and Sharp (1977). Hyb-
nrdisation mixtures of 20pi containing I0f c.p.m. of the labelled
probe (specific activity 10' c.p.m. gg '). 40jg RNA. 90% form-
amide. 400 mm NaCl. 40 mM Pipes, pH 6.5. 1 mM EDTA
were denatured at 90°C for S min and immediately transferred
to 58°C. After 15 h the hybridisation was terminated by addition
of 180 Al ice-cold buffer containing 250 mm NaCl. 30 m-m Na-
acetate. pH 4.5. 2 mM Zn-acetate. 50'o glycerol, and 400 units of
nuclease SI (Boehringer. Mannheim). The samples were incu-
bated at 25'C for 1 h. extracted twice with phenol-chloroform-
isoamylalcohol (25:24:1. vv v). and precipitated with ethanol.
Protected DNA fragments were separated on 500 polv.ac-
rylamide gels containing 7 M urea.
Nuclear run-on anal!ysis
Preparation of nuclear extracts and the hybridisation proce-
dure were performed as described (Eick & Bornkamm. 1986)
with slight modifications. 2 x 10' cells were scraped from
culture dishes and washed twice in PBS. Cells were
resuspended in 10 mm Tris-HCl. pH 7.4. 10 mm NaCl. 3 mM
MgC1.. 0.5% (v v) NP40 and incubated on ice for 5 mmn. The
nuclear pellets were spun down at 500 g and washed by
resuspension in 10 ml of the same buffer. The pelleted nuclei
were resuspended in storage buffer (50 mm Tris-HCl. pH 8.3.
40% (v v) glycerol. 5 mm MgCl2. 0.1 mm EDTA) and frozen
in liquid nitrogen in portions of 100 Al corresponding to
2 x 10 nuclei. The nuclei were mixed with 100 Al reaction
buffer (10 mM Tris-HCl. pH 8.0. 5 mm MgCl.. 300 m-m KCI.
0.5 mm. of each ATP. CTP, GTP and 100 zCi of (a-'2P) UTP
(800 Ci mmol. Amersham)) and incubated for 20 mn at
28°C. DNAseI was added to a final concentration of
10 jig ml-1 and the incubation was continued for 5 min at
28°C. After addition of 200 Al STE buffer (100 mM Tris-HCI.
pH 7.5. 50 m-M EDTA. 0.50% SDS) and 20 Ml proteinase K
(1Omg ml-. preincubated at 37°C for I h) the samples were
incubated for 1 h at 40'C. Nuclear transcripts were separated
from unincorporated nucleotides on a Sephadex G-50 col-
umn equilibrated with 10 mM Tn's-HCI. pH 7.5. 1 m.m
EDTA. 1% SDS. The labelled RNA was boiled for Omin,
chilled on ice and hybridised to DNA immobilised on nylon
filters (PALL) in Church-buffer (0.5m sodium phosphate. pH
7.1. 700 SDS. 0.1 mm EDTA) after preincubation of the filter
in the same buffer. After hybridisation the filters were washed
twice at 50'C in 0.1 x SSC. 1% SDS, twice in 2 x SSC
containing 1O0gml-1 RNAase A at 25'C and finally once
again in 0.1 x SSC. 1% SDS at 50°C. The filters were
exposed to Kodak XAR-5 fihms using a Dupont Cronex
Lightning Plus intensifying screen.
Results
Down-regulation of c-myc RVA in response to synthetic
androgen is slow
The effect of the synthetic androgen mibolerone (7a-17a-
Dimethyl-19-nortestosterone) on c-mvc expression in LNCaP
Figure 1 Genomic map of the human c-mv c gene depicting the
probes used in this work- P0. P,. P. and P, designate the four
c-m! c promotors. Abbreviations of restnrction enzymes: H =
HindIl. Sm = SmaI. X = Xhol. P = PvuII. S = Sacl. B = BstEIl.
C = ClaI. and E = EcoRI.
cells was studied. Cells were incubated for 0-120 h in the
presence or absence of 3.3 x 10' M mibolerone followed by
RNA extraction. Steady state c-mYc RNA levels were
analysed by Northern blotting using an exon 3-specific probe.
The structure of the c-mvc gene and all probes used in this
work are depicted in Figure 1. When LNCaP cells are main-
tained in the presence of mibolerone a decline in c-mvc RNA
levels becomes clearly visible after 12-48 h (Figure 2a). After
72 h. the amount of c-mvc RNA decreases to about 10o0 of
control cells. but is still detectable in Northern blots. As
shown in Figure 2b. the decrease of c-m!vc RNA is
monophasic. In LNCaP control cells c-mvc RNA levels begin
to decline slightlN after 24 h. and reach about 60°o of the
starting value after 120 h. RNA levels of the housekeeping
enzyme glyceraldehyde-phosphate-dehydrogenase (GAPDH)
did not change significantly during the experiment. Thus. the
substantial reduction of c-mvc RNA levels bv androgen is a
late effect. Androgen does not trigger anv earls down-
regulation of c-mvc. The effect of mibolerone is reversible;
48 h after withdrawal of the hormone c-mvc steady-state
RNA reached pretreatment levels (data not shown).
Excess antiandrogen represses c-mvc dowsn-regulation
If c-mvc down-regulation is mediated by the androgen recep-
tor. the effect of mibolerone must be suppressed by the
simultaneous addition of antihormone which competes with
androgen for specific receptor binding. In previous work
(Wolf et al.. 1991) we found that a large excess of the
antiandrogens cyproterone acetate (CA) or hvdroxyfutamide
is required to antagonise growth related effects of synthetic
androgens in LNCaP cells. CA has a much lower affinitv for
the androgen receptor than synthetic androgens with a 17a-
methyl-testosterone backbone (Wakeling et al.. 1981). The
suppression of c-m} c RNA levels is counteracted bv the
antiandrogen CA (Figure 2c) at the same concentration ratio
(1:750 w w) at which the growth inhibiting effect of andro-
gens on LNCaP cells is reversed (Wolf et al.. 1991). This
finding indicates that the androgen receptor is involved in the
signal transduction chain leading to c-mvc down-regulation
and to inhibition of proliferation by synthetic androgen.
The levels ofPI, P., and P0 transcripts decline, whereas P3
transcripts remain almost constant
In order to resolve the contribution of the four known c-mvc
promoters to the steady-state c-mvc signal seen in Northern
blots, we performed nuclease SI protection assays with pro-
bes derived from the promoter region of the human c-mvc
gene. Southern analysis of the c-mvc locus of LNCaP cells
revealed no rearrangement or amplification (data not shown).
Therefore. the expected sizes of SI protected fragments were
calculated on the basis of the germline configuration of the
human c-m} c gene. As shown in Figure 3a. the ratio of
P2:P,:Po transcripts in control cells is about 80:20:3. This
ratio is not changed in the presence of mibolerone. PI, P2 and
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P0 transcripts are reduced to the same extent (Figure 3a). In
contrast, P3 transcripts which comprise only 3/5% of the
total c-myc transcripts in LNCaP cells, remain at a level
almost equal to controls in the presence of mibolerone
(Figure 3b). Regulation of the P3-promoter independently of
the P0- PI-, and P2-promoter has recently been reported for
the normal c-myc allele in the Burkitt's lymphoma cell line
Raji (Eick et al., 1990).
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Fge 2 Northern blot analysis of total RNA of LNCaP cells after treatment with the synthetic androgen mibolerone and the
anti-androgen cyproterone acetate. LNCaP cells were cultivated in the presence (+) or absence (-) of 3.3 x 10- M mibolerone
(MIB) for various periods from 0- 120 h. RNA was extracted and analysed on Northern blots (20yig per lane) hybridised with a
c-mi-c third exon specific probe labelled by random priming (Clal-EcoRI. 1.4 kb. probe c in Figure 1). Subsequently, the probe was
washed off and the filter was rehybridised with a glyceraldehyde-phosphate-dehydrogenase (GAPDH)-specific probe (Allen et al..
1987) a, The autoradiograms were scanned densitometrically and c-myc RNA levels normalised to GAPDH RNA levels are shown
schematically in a block diagram b, The effect of mibolerone is antagonised by cyproterone acetate (CA) (1.8 x 10-' M). LNCaP
cells were incubated in the presence of MIB and CA as indicated and RNA was extracted after 48 h c.
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Figue 3 C-mwc promoter usage in LNCaP cells. The RNAs described in Figure 2a were subjected to SI analysis with probes specific for the four c-mvc promoters P0, P1. P. and P3. RNA derived from the P0-promoter was indirectly. RNA derived from
promoter P1 and P. directly visualised by a uniformly labelled. single-stranded SmaI-PvuII probe (probe a, Figure 1). PO-RNA protected a fragment of 614 bases, PI-RNA of 513 bases, and P-RNA of 351 bases a. Expression of P3-RNA was studied in cells treated for 72 h with (+) or without (-) mibolerone. P3-RNA was analysed with a double stranded XhoI-BstEII fragment (probe d, Figure 1) labelled at the BstEII site by T4 polynucleotide kinase. The probe protected a fragment of 322 bases corresponding to spliced P0-, PI-, and P,-RNA b. The bands at 770 bases are specific for P3-RNA. A long exposure of lanes 4 and 5 is shown at the right hand side. BL67 is a Burkitt's lymphoma cell line with a t(8; 14) translocation and served as a positive control for expression of P3-RNA (Eick et al., 1985).
C-myc is down-regulated at the level oftranscription initiation
C-myc RNA is subject to an unusually rapid turnover (Dani
et al., 1984). In several cellular systems, c-myc RNA stability
is the primary control mechanism to modulate steady-state
levels (for review see Piechaczyk et al., 1987). We have
determined the contribution of posttranscriptional mechanisms
to c-myc RNA repression in LNCaP cells and measured the
stability of c-myc RNA after addition of actinomycin D. In
the absence and presence (24 h) of mibolerone the half life of
c-myc RNA was measured to be 15 to 20 min (data not
shown). Therefore, a considerable contribution of a post-
transcriptional mechanism is unlikely, and we have studied
transcriptional control of c-myc RNA levels in nuclear run-
on experiments. This method measures the density of actively
transcribing RNA-polymerase II molecules on individual
segments of the c-mvc gene and allows to estimate the rate of
c-myc RNA initiation and elongation.
In LNCaP control cells similar signals were obtained for
the transcription rate of c-myc exon 1, 2. and 3 (Figure 4). However, the probe used for exon I has a size of 446 bases
and is more than 3-fold smaller than the exon 2 and 3 probes with 1533 and 1405 bases, respectively. The relatively high transcription rate of c-myc exon I compared to exon 2
indicates that a fraction of RNA polymerases becomes
blocked on the way to exon 2. A block to RNA-elongation in the c-myc gene has been described at the boundary of exon
I to intron I in many different cellular systems (for review
see Spencer & Groudine, 1990).
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In the presence of mibolerone, the density and distribution
of RNA polymerases on the c-myc gene remained unchanged
for the first 3 h. Subsequently, transcriptional activity de-
clined over a period of 2 days to about 10% of controls. The
transcription of exon 1 and exon 2 slowed down with a
similar rate. However the data presented in Figure 4 do not
rule out a contribution of the RNA-elongation block for
c-myc down-regulation between 6 and 12h. In the presence
of mibolerone and antihormone, transcription of c-myc was
unaffected over a period of 2 days (data not shown).
The transcription rate for the PSA (prostate-specific
antigen [Schulz et al., 1988D gene was increased 3 h after
addition of mibolerone and subsequently declined towards
pretreatment levels after 4 days (Figure 4). Thus, the decrease
in c-myc transcription is not due to a general decrease in
RNA synthesis concomitantly to inhibition of cell prolifera-
tion.
ENscussio
The synthetic androgen mibolerone is capable of triggering a
set of fundamental changes in the growth behaviour of
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Fge 4 Transcriptional run-on activity of the c-mc gene in
mibolerone treated LNCaP cells. 5 g of single-stranded DNA
fragments cloned in M13 and specific to c-me exon I and 2
(fragments e and b. Figure 1) were separated in a 1.2% agarose
gel and transferred to nylon filters by Southern blotting. The
probes marked (+) detect c-mic sense transcripts and (-) detect
antisense transcripts. The exon 3 probe is a double-stranded
purified Clal-EcoRI fragment (probe c. Figure 1). PSA is a probe
for the prostate-specific antigen (1.5 kb EcoRI cDNA fragment
[52D. The ethidium bromide stained gel before transfer is shown
at the top. Filters were hybridised with nuclear run-on RNA (10'
c.p.m. 3 ml hybridisation buffer) from LNCaP cells treated with-
out (Oh) or with mibolerone for 3-96 h.
LNCaP cells: inhibition of proliferation, abrogation of
anchorage-independent growth, morphological change, and
reduction of c-myc RNA levels (Wolf et al., 1991). The signal
transduction pathway from androgen binding to the ultimate
cellular responses remains to be elucidated. In this report, the
level of c-myc down-regulation by mibolerone in LNCaP cells
has been analysed.
Mibolerone induces a late transcriptional repression of
c-myc in LNCaP cells. The trancription rate for c-myc exon 1
and 2 decreased with a similar rate 3 to 6 h after addition of
hormone. Thus, a reduced rate ofRNA-elongation which has
been described as fast control mechanism in c-myc down-
regulation (Eick & Bornkamm, 1986) does not significantly
contribute to c-myc repression in LNCaP cells. Mibolerone
represses c-myc at the level oftranscription initiation. The lag
phase between hormone addition and the decline of c-mvc
transcription (>3 h) indicates that androgen receptor-
mediated repression of c-myc involves additional regulatory
steps.
Androgen regulation of c-myc has also been studied in
vivo. C-myc RNA in the ventral prostate epithelial cells of
rats increases nearly 4-fold within 1 day and 6- to 7-fold
within 2 days after castration. The castration induces atrophy
of prostatic epithelial cells while androgen treatment causes
an increase in cell size and number. Administration of tes-
tosterone at the time of castration prevents the atrophy and
the increases in c-myc RNA levels (Quarmby et al., 1987).
Similar observations were made studying the regression of
androgen-dependent Shionogi mouse mammary carcinoma
cells in castrated syngeneic animals. 3-6 days after castration
the tumour mass began to regress accompanied by a con-
tinuous increase of c-myc RNA (Rennie et al., 1988).
Repression of c-m}yc has also been reported for other
steroid hormones. Glucocorticoids induce growth inhibition
and c-myc repression in the human T lymphoblastic
leukaemic cell line CCRF-CEM (Yuh & Thompson, 1989), in
mouse lymphoma cells (Eastman-Reks & Vedeckis, 1986), in
oestrogen-treated oviducts of immature chickens (Rories et
al., 1989), and in the murine lymphosarcoma cell line P1798
(Forsthoefel & Thompson, 1987). A direct transcriptional
repression of the murine c-m)c gene by binding of the
glucocorticoid receptor complex to a response element up-
stream of exon 1 has been discussed as a possible mechanism
of c-myc shutoff (Forsthoefel & Thompson, 1987).
The response elements for the glucocorticoid and androgen
receptor share the imperfect palindrome GGTACANN-
NTGTTCT (Beato, 1989). In the androgen-regulated C3 gene
of rat prostate androgen response is conferred by an element
in the first intron (Claessens et al., 1989). This element
AGTACGTGATGTTCT differs in only two positions of the
left hand part to the consensus sequence. The first intron of
the c-m}vc gene harbours also a potential glucocorticoid/
androgen receptor binding site GGTAGCAGCTG1TCT
which diverges in two positions. All elements have the TGT-
TCT motif in common which has been shown to be func-
tionally important for glucocorticoid and androgen response.
Whether glucocorticoid and androgen receptors can bind to
the described element in the first intron of c-mvc has yet to
be proven.
Alternatively, steroid-receptor complexes may exert their
negative effect on c-my expression without direct binding to
a response element. The glucocorticoid receptor (GR) and
the transcription factor API can reciprocally repress one
another's potency to activate transcription. In this particular
antagonistic relationship, the negative factor (GR) does not
displace the positive transcription factor (API) from its res-
ponse element, but appears to interact directly with API
(Jonat et al., 1990, Yang-Yen et al., 1990; Schuile et al.,
1990). Thus, glucocorticoids may repress c-myc by direct
binding to API located at a binding site which has been
described 330bp upstream of the P,-promoter. This region
has been identified as negative element for c-myc transcrip-
tion (Hay et al., 1987; Takimoto et al., 1989; Hay et al.,
1989). Whether the androgen receptor can reduce transcrip-
tion initiation of c-myc via API binding is not yet known.
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In vivo androgen has a key-role in the maintenance of
prostate cells. The hormone preserves the differentiated state
of the cells and represses c-mvc. High expression of c-mvc
accomphshed by a retroviral vector results in benign hyper-
plasia in a reconstituted prostate model (Thompson et al.,
1989). Thus, regulation of c-myc in prostate cells by and-
rogen is evident. However, the precise role of c-mi)c in
growth control of normal and neoplastic prostate cells re-
mains to be elucidated.
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